Physician profile
Steven F Ellis
NPI 1942354246
$108,979.91
in general payments reported to CMS, 2019-2025
21 companies · $26K in 2025
The $26K reported for 2025 was more than what 98% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $6,355 · 2021: $22K · 2022: $16K · 2023: $15K · 2024: $24K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $5,436 · Food and Beverage: $2,384 · Education: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,372.87 |
| Travel and Lodging | $5,435.90 |
| Food and Beverage | $2,384.08 |
| Education | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $79,775.88 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $27,533.07 | 2020-2025 | Dupixent |
| Intersect Ent, INC. | $365.24 | 2020-2021 | |
| Stryker Corporation | $343.78 | 2019-2024 | Core |
| Eisai INC. | $275.53 | 2021-2022 | |
| Glaxosmithkline, LLC. | $175.88 | 2023-2025 | Nucala, Bexsero, Shingrix |
| Acclarent, INC | $103.97 | 2019-2023 | Trudi Nav Cable, Acclarent Aera |
| Phathom Pharmaceuticals, INC. | $65.03 | 2024-2025 | Voquezna |
| Hikma Pharmaceuticals USA | $54.57 | 2024-2025 | Ryaltris |
| Optinose US, INC. | $43.48 | 2024-2025 | |
| Aerin Medical INC. | $35.28 | 2024 | |
| Merz Pharmaceuticals, LLC | $34.43 | 2022-2023 | Xeomin |
| Organogenesis INC. | $29.00 | 2022 | |
| Depuy Synthes Sales INC. | $25.53 | 2021 | |
| Medtronic, INC. | $21.74 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.49 | 2023 | |
| Integra Lifesciences Corporation | $20.19 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Lundbeck LLC | $18.86 | 2019 | |
| Baudax Bio INC. | $16.97 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.51 | 2022 | |
| Endogastric Solutions, INC | $8.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.